Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on May 8, 2023, at 4:30 PM ET to discuss a business update and report first quarter 2023 financial results. Investors can join the call by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (international) and using passcode 2096044. A live webcast will also be available through the investor relations section on the Corvus website.
Corvus Pharmaceuticals is focused on developing novel therapies for cancer. Its lead candidate, CPI-818, is in a Phase 1/1b trial aimed at T cell lymphomas, while two additional programs, CPI-444 and CPI-006, are also in various stages of clinical trials. The company continues to advance its innovative pipeline in the biopharma sector.
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced promising preclinical data for its investigational drug CPI-818, an ITK inhibitor aimed at treating various cancers. The data, presented at the AACR Annual Meeting, indicates CPI-818 effectively inhibits tumor growth in models of colon, renal, and melanoma cancers, as well as T and B cell lymphomas. The mechanism of action involves enhancing T cell differentiation and reducing T cell exhaustion, potentially positioning CPI-818 for broad cancer immunotherapy applications. The company is currently enrolling patients in a Phase 1/1b trial focusing on T cell lymphoma and plans to meet with the FDA to discuss a Phase 3 trial. Corvus anticipates presenting updated clinical trial data in the second quarter of 2023.